Alpha emitting constructs and uses thereof

Details Alpha emitting constructs and uses thereof Alpha emitting constructs and uses thereof

2000-11-24

2010-06-15

Helms, Larry R. (Department: 1642)

Drug, bio-affecting and body treating compositions

Conjugate or complex of monoclonal or polyclonal antibody,...

C424S155100, C530S387100, C530S391300

Reexamination Certificate

active

07736651

ABSTRACT:
The present invention discloses alpha particle emitting, radioactive constructs capable of killing large tumors (>1 mm in diameter), or other cells involved in human or animal diseases such as virus infected cells, autoimmune cells, or other pathological cells, including normal cells, that are targets for destruction, to achieve a therapeutic result. The alpha emitting constructs have high specific activity.

REFERENCES:
patent: 4444744 (1984-04-01), Goldenberg
patent: 4665897 (1987-05-01), Lemelson
patent: 6197278 (2001-03-01), Blankenberg et al.
patent: 0 282 057 (1988-03-01), None
patent: 0 585 986 (1993-07-01), None
patent: WO 91/09058 (1991-06-01), None
Adams, G.P. Nuclear Med. Biol. 27: 339-346, 2000.
Hartman. Cancer Res, 54: 4362-70, 1944.
Horak, E J. Nuclear Med. 38(12): 1944-50, 1997.
Kasperson, FM. Nuclear Med. Com. 16: 468-476, 1995.
Simonson et al, 1990, Cancer Res, 50 (3 Supp): 9855-9885.
Maloney DG et al, 1994, Blood, 84 (8): 2457-66.
Vieira, MR, et al, 1996, Eur J Surgical Oncology, 22(4): 331-4.
Hager J C et al, Cancer Res, 1982, 42 (11): 4325-9.
Kemshead J T et al, 1982, Brain res, 236 (2): 451-61.
Greiner J W et al, 1987, J lab clin med, 109(3): 244-61.
Smith, B D, 2001, Annals Otology, rhinology, and laryngology, 110 (3): 221-8.
Friedel G et al, 1994, Minimally invasive therapy, 3(3): 169-172.
Kozak et al, 1986, PNAS, USA, 83(2): 474-8.
McDevitt M. R. et al. Bismuth Labeled Antibodies for Therapy of Prostate Carcinomas: Preclinical Studies.Journal of Nuclear Medicine, Society of Nuclear Medicine, vol. 39, No. 5, 1998, pp. 223-224.
Larsen R.H. et al. Intratumour injection of immunoglobulins labelled with the α-particle emitter 211 At: analyses of tumour retention, microdistribution and growth delay.British Journal of Cancer. vol. 77, No. 7, 1998, pp. 1115-1122.
Sgouros G. et al. Pharmacokinetics and dosimetry of and alpha-particle emitter labeled anti-CD33 antibody ((213Bi)HuM195) in patients with leukemia.Journal of Nuclear Medicine. vol. 38, No. 5, 1997, pp. 231.
Jurcic J. G. et al. Targeted alpha-particle therapy for myeloid leukemias: A phase I trial of bismuth-213-HuM195 (anti-CD33).Memorial Sloan-Kettering Cancer Center. vol. 90, No. 10, 1997, pp. 504A.
Kennel S. et al. Vascular Targeted Radioimmunotherapy with 213Bi-An α-Particle Emitter.Nuclear Medicine&Biology. vol. 25, No. 3, 1998, pp. 241-246.
Liu, H. et al. Monoclonal Antibodies to the Extracellular Domain of Prostate-specific Membrane Antigen Also React with Tumor Vascular Endothelium1.Cancer Research. vol. 57, 1997, No. 17 pp. 3629-3634.

Affiliated with

Also associated with

Rating

Alpha emitting constructs and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Alpha emitting constructs and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alpha emitting constructs and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4184021